Aquestive Therapeutics (NASDAQ:AQST) announced its earnings results on Thursday. The company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.91) by $0.35, MarketWatch Earnings reports. The business had revenue of $16.82 million for the quarter, compared to analyst estimates of $17.05 million. Aquestive Therapeutics updated its FY 2019 guidance to EPS.
Shares of AQST stock traded up $0.17 on Friday, hitting $6.54. The stock had a trading volume of 600 shares, compared to its average volume of 114,662. The company has a debt-to-equity ratio of 1.88, a quick ratio of 3.42 and a current ratio of 3.63. Aquestive Therapeutics has a 52-week low of $5.60 and a 52-week high of $20.70.
Several hedge funds have recently made changes to their positions in AQST. Geode Capital Management LLC grew its holdings in Aquestive Therapeutics by 77.6% in the 4th quarter. Geode Capital Management LLC now owns 44,208 shares of the company’s stock valued at $278,000 after buying an additional 19,310 shares in the last quarter. Millennium Management LLC bought a new position in Aquestive Therapeutics in the 4th quarter valued at about $145,000. Squarepoint Ops LLC bought a new position in Aquestive Therapeutics in the 4th quarter valued at about $188,000. Perceptive Advisors LLC grew its position in Aquestive Therapeutics by 83.8% in the 4th quarter. Perceptive Advisors LLC now owns 2,113,400 shares of the company’s stock valued at $13,314,000 after buying an additional 963,400 shares in the last quarter. Finally, Bank of New York Mellon Corp bought a new position in Aquestive Therapeutics in the 4th quarter valued at about $108,000. Institutional investors and hedge funds own 58.34% of the company’s stock.
Several research firms have issued reports on AQST. Lake Street Capital began coverage on shares of Aquestive Therapeutics in a research note on Thursday, January 3rd. They set a “buy” rating and a $14.00 price objective for the company. Wedbush set a $30.00 price objective on shares of Aquestive Therapeutics and gave the stock a “buy aqst” rating in a research note on Thursday, December 20th. Finally, Zacks Investment Research downgraded shares of Aquestive Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, November 20th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $23.60.
Aquestive Therapeutics Company Profile
Aquestive Therapeutics, Inc, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. Its products are developed using its PharmFilm technology. The company's marketed products include Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron antagonist for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery.
Read More: Sell-Side Analysts
Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.